Pascal Biosciences is dedicated to improving the lives of patients suffering from life-threatening diseases including COVID-19 and intractable cancers such as glioblastoma. We are developing novel cannabinoid-based small molecules and targeted antibodies, focusing on treatments for SAR-CoV-2 infection and cancers for which there are no adequate therapies.
Cannabinoid for COVID-19
In a cell-based assay, Pascal has identified a cannabinoid that blocks SARS-CoV-2 with a potency similar to remdesivir.
PAS-403 for Glioblastoma
PAS-403 is a cannabinoid-based small molecule that utilizes a unique mechanism of action to kill cancer cells. Clinical trials are targeted to begin in 2021.
PAS-393 for Cancer
PAS-393 is a cannabinoid that makes cancers visible to the immune system.
